Orally active prostacyclin analogue for cardiovascular disease

Area of Science:

• Cardiovascular Pharmacology
• Vascular Biology
• Drug Development

Background:

• Prostacyclin exhibits vasoprotective properties, including vasodilation and antiplatelet activity.
• A deficiency in prostacyclin is implicated in cardiovascular diseases like pulmonary artery hypertension (PAH).
• Intravenous prostacyclin administration poses challenges, necessitating the development of oral alternatives.

Purpose of the Study:

• To evaluate the therapeutic potential of beraprost, an orally active prostacyclin analogue.
• To investigate beraprost's effects on neovascularization and cardiovascular events.
• To establish beraprost as a promising treatment for cardiovascular diseases.

Main Methods:

• Review of existing literature on prostacyclin and beraprost.
• Analysis of clinical studies involving beraprost for peripheral arterial disease (PAD).
• Examination of beraprost's mechanism in inducing neovascularization via bone marrow cell mobilization.

Main Results:

• Beraprost, a stable oral prostacyclin analogue, demonstrates potent vasodilation and antiplatelet aggregation.
• Beraprost has been successfully used in treating PAH and PAD.
• Beraprost enhances bone marrow cell mobilization, inducing neovascularization in ischemic myocardium.
• Meta-analysis of PAD studies indicates beraprost administration reduces cardiovascular events.

Conclusions:

• Oral beraprost exhibits significant vasoprotective and neovascularization-inducing effects.
• Beraprost represents a promising therapeutic agent for managing cardiovascular diseases.
• The development of orally active prostacyclin analogues offers a convenient and effective treatment strategy.